CPA3: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: CPA3

NCBI ID: G1359

CPA3

CPA3: A Potential Drug Target Or Biomarker for Various Diseases

CPA3 (CBPA3_HUMAN), a protein that belongs to the superfamily of G-protein-coupled receptors (GPCRs), has been identified as a potential drug target or biomarker for various diseases, including cancer, anxiety, and depression. Its unique structure and function make it an attractive target for drug development due to its robust pharmacokinetic and pharmacodynamic properties.

CPA3 is a 12-kDa transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in the protein's anchorage to the cell surface, while the transmembrane domain is responsible for the protein's structure and function. The intracellular domain is involved in the protein's interactions with intracellular signaling pathways.

CPA3 plays a crucial role in various physiological processes in the body, including glucose and insulin signaling, stress response, and neurotransmitter signaling. It is involved in the regulation of glucose metabolism, insulin sensitivity, and inflammation. CPA3 has been shown to play a key role in the development and progression of type 2 diabetes, insulin resistance, and obesity.

CPA3 is also involved in the regulation of stress and anxiety responses. It has been shown to play a critical role in the regulation of neuroinflammation, anxiety, and depression. CPA3 has been shown to interact with various signaling pathways, including TGF-β, NF-kappa-B, and ERK. These signaling pathways are involved in the regulation of stress response, inflammation, and neurotransmission.

CPA3 is also involved in the regulation of pain perception and neurotransmission. It has been shown to play a critical role in the regulation of pain perception and neurotransmission, including the modulation of pain sensitivity and the modulation of neurotransmitter release. CPA3 has been shown to interact with various signaling pathways, including TRPV1 and GPR117. These signaling pathways are involved in the regulation of pain perception and neurotransmission.

CPA3 is also a potential biomarker for various diseases, including cancer, anxiety, and depression. Its expression has been shown to be affected by various diseases, including cancer, obesity, and neurodegenerative diseases. CPA3 has also been shown to play a critical role in the regulation of cancer cell growth and metastasis.

In conclusion, CPA3 is a protein that has been identified as a potential drug target or biomarker for various diseases. Its unique structure and function make it an attractive target for drug development due to its robust pharmacokinetic and pharmacodynamic properties. Further research is needed to fully understand the role of CPA3 in various diseases and to develop effective therapies that target this protein.

Protein Name: Carboxypeptidase A3

The "CPA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets